[Sensitivity testing of malignant human tumors against cytostatic agents. II].
D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D004273:DNA, Neoplasm / Q000096:biosynthesis; D005260:Female; D006801:Humans; D007414:Intestinal Neoplasms / Q000188:drug therapy*; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D011344:Procarbazine / Q000627:therapeutic use; D013274:Stomach Neoplasms / Q000188:drug therapy*; D014228:Triaziquone / Q000627:therapeutic use
D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D011344:Procarbazine; D014228:Triaziquone; D008727:Methotrexate
Zur Sensibilitätstestung maligner menschlicher Tumoren gegenüber Cytostatica. I.